
Docket No.: GNE.3230R1C160



1

INFORMATION DISCLOSURE STATEMENT

plicant

Goddard, et al. (as amended)

App. No

10/063,732

Filed

May 8, 2002

For

A NUCLEIC ACID

OVEREXPRESSED IN ESOPHAGEAL

AND LUNG TUMOR, AND

UNDEREXPRESSED IN KIDNEY

TUMOR AND MELANOMA

Examiner

Seharaseyon, J.

Art Unit

1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

> July 18, 2005 (Date)

AnneMarie Kaisel, Reg. No. 37,649

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 45 references to be considered by the Examiner. Also enclosed are 32 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed within three months of the filing date, with an RCE or before receipt of a first office action after an RCE and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Registration No. 37,649

Attorney of Record

Customer No. 30,313

(619) 235-8550

1818577:071805

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No. 10/063,732

Filing Date May 8, 2002

First Named Inventor Goddard, et al. (as amended0

Art Unit 1647

Examiner Seharaseyon, J.

Attorney Docket No. GNE.3230R1C160

CMultiple sheets used when necessary)
SHEET 1 OF 3

U.S. PATENT DOCUMENTS Pages Columns Lines Where						
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
:	1	6,025,156	02-15-2000	Gwynn, et al.		
	2	6,124,433	09-26-2000	Falb, et al.		
	3	6,156,500	12-05-2000	Falb, D.		
	4	6,162,604	12-19-2000	Jacob, Chaim O.		
	5	6,228,582 B1	05-08-2001	Rodier, et al.		
	6	6,395,306 B1	05-28-2002	Cui, et al.		
	7	6,414,117 B1	07-02-2002	Levinson, D. A.		
	8	6,465,185 B1	10-15-2002	Goldfine, et al.		
	9	6,498,235 B2	12-24-2002	Sheppard, et al.		
	10	6,562,343 B1	05-13-2003	Levinson, D. A.		
	11	6,645,499 B1	11-11-2003	Lal, et al.		
	12	6,730,502 B2	05-04-2004	Van Hijum, et al.		
	13	6,737,522 B2	05-18-2004	Sundick, et al.		

			FOREIGN PATE	ENT DOCUMENTS		
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	14	WO 97/38085	10-16-1997	California Pacific Medical Center		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	15	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell, 3rd Edition</i> , pp. 403-404, 453. New York: Garland Publishing.	
	16	ALBERTS, et al. 2002. Molecular Biology of the Cell 4th Edition, pp. 302, 363-364, 379, 435. New York: Garland Publishing.	
	17	ALLMAN, et al. 1996. BCL-6 expression during B-cell activation. <i>Blood</i> , 87(12):5257-5268.	
	18	CHEN, et al. 2002. Discordant protein and mRNA expression in lung adenocarcinomas. <i>Molecular & Cellular Proteomics 1.4</i> , pp. 304-313.	

F	!	. ^	ature
-va	minai		1211110
		Olui	latuic

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATIO	N D	ISCLO	SURE
-STATEMENT	RV	A DDI	ICANIT

Application No. 10/063,732

Filing Date May 8, 2002

First Named Inventor Goddard, et al. (as amended0

Art Unit 1647

Examiner Seharaseyon, J.

Attorney Docket No. GNE.3230R1C160

Multiple sheets used when necessary)

SHEET 2 OF 3

ENT & TRADE!		NON PATENT LITERATURE DOCUMENTS	•
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	19	FESSLER, et al. 2002. A genomic and proteomic analysis of activation of the human neutrophil by lipopolysaccharide and its mediation by p38 mitogen-activated protein kinase. <i>The Journal of Biological Chemistry</i> , 277(35):31291-31302.	
	20	FU, et al. 1996. Translational regulation of human p53 gene expression. <i>The EMBO Journal</i> , 15(16):4392-4401.	
	21	GÖKMEN-POLAR, et al. 2001. Elevated protein kinase C ßII is an early promotive event in colon carcinogenesis. <i>Cancer Research</i> , 61:1375-1381.	
	22	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.	
	23	GYGI, et al. 1999. Correlation between protein and mRNA abundance in yeast. <i>Molecular and Cellular Biology</i> , 19(3):1720-1730.	
	24	HANASH, S. 2003. Making sense of microarray data to classify cancer. The Pharmacogenomics Journal, 3:308-311.	
	25	HANASH, S. March 2005. Integrated global profiling of cancer. <i>Nature Reviews, Applied Proteomics Collection</i> , pp. 9-14.	
	26	HANCOCK, W. S. 2004. Do we have enough biomarkers? Journal of Proteome Research, 3(4):685.	
	27	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. <i>Pathology Associates Medical Laboratories</i> .	
	28	HAYNES, et al. 1998. Proteome analysis: Biological assay or data archive? <i>Electrophoresis</i> , 19:1862-1871.	
	29	HU, et al. 2003. Analysis of genomic and proteomic data using advanced literature mining. <i>Journal of Proteome Research</i> , 2:405-412.	
	30	HYMAN, et al. 2002. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Research, 62:6240-6245.	
	31	JANG, et al. 1997. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastatis-associated genes in murine tumor cells. <i>Clin. Exp. Metastasis</i> , 15(5):469-483. (Abstract).	
	32	KONOPKA, et al. 1986. Variable expression of the translocated <i>c-abl</i> oncogene in Philadelphia-chromosome-positive B-lymphoid cell lines from chronic myelogenous leukemia patients. <i>Proc. Natl. Acad. Sci. USA</i> , 83:4049-4052.	
	33	LEWIN, B. 1994. Oncogenes: Gene expression and cancer, Chap. 39, pp. 1196-1201. <i>Genes V.</i> New York: Oxford University Press.	
	34	LEWIN, B. 1997. Regulation of Transcription, Chap. 29, pp. 847-848. <i>Genes VI</i> . New York: Oxford University Press.	
	35	MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. <i>Blood</i> , 76(2):285-289.	
	36	MERIC, et al. 2002. Translation intiation in cancer: A novel target for therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.	

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Multiple sheets used when necessary)

SHEET 3 OF 3

Application No.	10/063,732
Filing Date	May 8, 2002
First Named Inventor	Goddard, et al. (as amended0
Art Unit	1647
Examiner	Seharaseyon, J.
Attorney Docket No.	GNE.3230R1C160

111 2 0 2005

61

Es.	34	NON PATENT LITERATURE DOCUMENTS	
Examinado Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	37	OHARA, et al. 2001. Directional cDNA library construction assisted by the <i>in vitro</i> recombination reaction. <i>Nucleic Acids Research</i> , 29(4):e22 p. 1-8.	
	38	ØRNTOFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular & Cellular Proteomics</i> , 1:37-45.	
	39	POLLACK, et al. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>PNAS</i> , 99(20):12963-12968.	
	40	POWELL, et al. 1998. Expression of cytochrome P4502E1 in human liver: Assessment by mRNA, genotype and phenotype. <i>Pharmacogenetics</i> , 8:411-421. (Abstract).	
	41	SINGLETON, et al. 1992. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. Pathol. Annu., 1(27):165-190.	
	42	VALLEJO, et al. 2000. Evidence of tissue-specific, post-transcriptional regulation of NRF-2 expression. Biochimie, 82(12):1129-1133. (Abstract).	
	43	WANG, et al. 1996. mRNA Differential display: Application in the discovery of novel pharmacological targets. <i>Trends Pharmacol. Sci.</i> , 17(8):276-279.	
	44	ZHIGANG, et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. World Journal of Surgical Oncology, 2:13.	
	45	2002-2003 Catalog & Technical Reference, New England BioLabs, Inc., p. 122.	

1818558 071805

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.